Back to News
Security News

Spotlight On: Lantus® / Lantus® SoloSTAR® (insulin glargine recombinant) / Basaglar® (insulin glargine) / Semglee® (insulin glargine) / Rezvoglar™ (insulin glargine-aglr) - April 2026

UnknownApr 16, 2026(24 days ago)

The article discusses patent claim challenges related to Insulin Glargine products in IPR and litigation.

Insulin Glargine Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once. Within each IPR, claims are counted only once, whether they are challenged under § 102, § 103, or both. Claims in litigations are determined based on claims alleged infringed in... By: Venable LLP

Related News

Get Personalized Alerts

Track vendors and receive alerts when security incidents affect your supply chain.

What We Monitor

Security Incidents

Data breaches, ransomware, and unauthorized access

Vulnerabilities

CVEs and vendor security advisories

Compliance Updates

Regulatory changes and certification news

Legal News

Privacy laws and enforcement actions

Vendor Directory

Browse our directory of SaaS vendors with security documentation and compliance information.